Biopharma AI
By
FDA Qualifies First AI Drug Development Tool, Will Be Used in ‘MASH’ Clinical Trials to Accelerate Liver Disease Drug Development
The U.S. Food and Drug Administration (FDA) has qualified AIM-NASH, the first AI-based tool designed to assist doctors…
How Novartis and Relation Therapeutics’ $1.7 Billion AI Collaboration Redefine Drug Discovery Success Rates in Immunology, Atopic Diseases?
Key Highlights: • AI-driven, patient-derived target discovery emerges as a new gold standard for reducing late-stage clinical failures•…
How Roche’s $55 Million Bet on Manifold Bio’s AI Brain-Shuttle Platform Unlock the Next Trillion-Dollar Neuroscience Opportunity?
Key Highlights• Roche deepens its AI-first drug discovery strategy with a foundational partnership targeting blood-brain barrier (BBB) breakthroughs•…
Will Lilly’s AI Supercomputer with NVIDIA Become the Breakthrough That Redefines Competitive Timelines in Drug Development?
• Lilly partners with NVIDIA to build what it calls the most powerful AI supercomputer operated by a…
Can Roche’s $420 Million AI Investment in 2025 — Backed by Strategic AI Deals — Boost Discovery, R&D, and Commercial Advantage in 2026?
Global – December 31, 2025 — Roche Holding AG, a global leader in pharmaceuticals and diagnostics, significantly expanded…
Can Novartis’ $480 Million AI Investment in 2025 — Bolstered by Strategic AI Deals — Accelerate Discovery, R&D, and Commercial Leadership in 2026?
Global – December 31, 2025 — Novartis International AG significantly expanded its investment in artificial intelligence (AI) across…
